---
title: "InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285725744.md"
description: "Jena, Germany - InflaRx N.V., a leading biopharmaceutical company focused on developing anti-inflammatory treatments for the complement system, has successfully concluded its underwritten offering of 75,000,000 ordinary shares at $2.00 per share. The total gross earnings from this offering amounted to $150 million, excluding underwriting fees and other associated costs."
datetime: "2026-05-08T12:17:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285725744.md)
  - [en](https://longbridge.com/en/news/285725744.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285725744.md)
---

# InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

Jena, Germany - InflaRx N.V., a leading biopharmaceutical company focused on developing anti-inflammatory treatments for the complement system, has successfully concluded its underwritten offering of 75,000,000 ordinary shares at $2.00 per share. The total gross earnings from this offering amounted to $150 million, excluding underwriting fees and other associated costs.

### Related Stocks

- [IFRX.US](https://longbridge.com/en/quote/IFRX.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Precigen Q1 revenue beats estimates on PAPZIMEOS launch](https://longbridge.com/en/news/286311056.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)